encapsulation - Nanbiosis

U6. Biomaterial Processing and Nanostructuring Unit

U6. Biomaterial Processing and Nanostructuring Unit

- Scientific Director: Prof. Nora Ventosa ventosa@icmab.es
- Scientific Coordinator: Dr. Eduardo Pérez eperez2@icmab.es
- Entities: Instituto de Ciencia de Materiales de Barcelona ICMAB-CSIC
- Address: Campus de UAB, 08193, Bellaterra, Barcelona, Spain
- Phone: +34 935 801 853
- Fax: +34 935 805 729
- Web: ICMAB

Order request

Description

Located at the Instituto de Ciencia de Materiales de Barcelona (ICMAB-CSIC), in Barcelona, and under the coordination of Professor Jaume Veciana and Prof. Nora Ventosa, current directors of NANOMOL Group, which is a research group with wide expertise and recognized excellence in the synthesis, processing and study of molecular and polymeric materials with chemical, electronic, magnetic and biomedical properties. It gathers several laboratories, perfectly equipped, to perform the mission of this facility: the development, characterization, and large-scale production of molecular biomaterials of therapeutic or biomedical interest, with controlled micro-, nano- and supramolecular structure. One example of Key-Enabling-Technology (KET) available in this unit is a simple one-step methodology, DELOS-SUSP, based on the use of compressed fluids (CF), such as CO2, to prepare particulate materials with precise and reproducible structural characteristics at micro-, nano- and supramolecular levels (size, shape, internal structural gradients, supramolecular organization and crystalline purity). This example shows one of the singularities of this unit is that counts with CF–based plants at different scales, from mL to L, which allow process development by QbD and process scale-up.

The NANBIOSIS Unit 6 is also applying for the ISO9001 certification forstandard quality control system

QUALITY COMMITMENT

QUALITY POLICY

Services

FOR THOSE SERVICES IDENTIFIED AS OUTSTANDING, AT LEAST 20% OF THEIR CAPACITY IS OPEN UNDER COMPETITIVE ACCESS. SEE ANNEX 1 OF ACCESS PROTOCOL FOR DETAILS ON % OF OPENNESS FOR EACH SERVICE

U6. Services & Rates

Equipments

Active projects

		Title	Fundin: Organism	Call: Funding source	Role
GA: 720942		SMART FUNCTIONAL GLA-NANOFORMULATION FOR FABRY DISEASE – Smart-4-Fabry	Unión Europea (Comisión Europea)	H2020-NMBP-2016-2017	Coordinator
SAF2017-90810-REDI		Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II	Agencia Estatal de Investigación (AEI)	Acciones de dinamización «REDES DE EXCELENCIA» -ICTS 2017	Coordinator

Other projects

Ref	Title	Funding Organism	Unit Role
PI15/00272	Design of intelligent nanoconjugates for the treatment of metastatic colorectal cancer.	Instituto de Salud Carlos III	Participant
H2020-MSCA-ITN-2014-642196	Integrated self-assembled SWITCHable systems and materials: towards responsive organic electronics - a multi-site innovative training action i-Switch	Unión Europea H2020	Participant
2014 SGR 17	Consolidation Research Group: Molecular Nanociènciai Materials Orgànics (NANOMOL)	Generalitat de Catalunya	Participant
CTQ2013-40480-R	Molecular Bio- and Electro-active materials for the improvement of health and social well-being (Be-Well)	MICINN	Participant
FP7-PEOPLE-2013-ITN nº 607721	Nanochemistry of molecular materials for 2-photon functional applications. Nano2Fun	Unión Europea	Participant
MAT2013-50036-EXP	Cell Surface Vessel Engineering Using Dynamic Molecular Bioinfecting (DYNAMO)	MINECO	Participant
RTC-2016-4567-1	Nanocapsules containing active ingredients for the topical treatment of dermatological diseases (NANO4DERM)	MINECO	Participant
RTC-2014-2183-S	Application of Quatsomes technology for the development of a new range of perfumed softeners with lower environmental impact	MINECO	Participant
201260E080	Self-assembly, Nanostructuring and Processing of Functional Organic Molecules and their Applications	Ministerio de Ciencia e Innovación	Participant
MAT2016-80826-R	Molecular materials and supramolecular organizations for therapy, diagnosis and tissue engineering (MOTHER)	MINECO	Participant
RTC-2014-2207-1	TERARMET: Development of therapies for the treatment of rare congenital metabolic diseases	MINECO	Participant

Publications

2016

Munoz-Gomez J.L., Monteagudo E., Lloveras V., Parella T., Veciana J., Vidal-Gancedo J.. Optimized polarization build-up times in dissolution DNP-NMR using a benzyl amino derivative of BDPA. RSC Advances. 2016;6(32):27077-27082.
Cordoba A., Hierro-Oliva M., Pacha-Olivenza M.A., Fernandez-Calderon M.C., Perello J., Isern B. et al. Direct Covalent Grafting of Phytate to Titanium Surfaces through Ti-O-P Bonding Shows Bone Stimulating Surface Properties and Decreased Bacterial Adhesion. ACS Applied Materials and Interfaces. 2016;8(18):11326-11335.
Cabrera I., Abasolo I., Corchero J.L., Elizondo E., Gil P.R., Moreno E. et al. α-Galactosidase-A Loaded-Nanoliposomes with Enhanced Enzymatic Activity and Intracellular Penetration. Advanced Healthcare Materials. 2016;5(7):829-840.
Cano-Garrido O., Sanchez-Chardi A., Pares S., Giro I., Tatkiewicz W.I., Ferrer-Miralles N. et al. Functional protein-based nanomaterial produced in microorganisms recognized as safe: A new platform for biotechnology. Acta Biomaterialia. 2016;43:230-239.

News U6

19 Jul

Radical Dendrimers as Contrast Agents for Magnetic Resonance Imaging

José Vidal Gancedo, researcher from ICMAB-CSIC and CIBER-BBN is leading the project VIRADEN: “In vivo Studies of Radical Dendrimers as Contrast Agents for Magnetic Resonance Imaging“, one of the ICMAB Frontier Interdisciplinary Projects (FIP) 2021. The project aims to evaluate the new contrast agents for MRI based on organic radical dendrimers developed in his group, to substitute the currently used contrast agents based on toxic metals, with the final goal of obtaining useful contrast agents in the early detection of tumors José Vidal has explained NANBIOSIS participation in the project through Biomaterial Processing and Nanostructuring equipments of NANBIOSIS U6 counting wit[...]

14 Jul

Study of new liposomes for the delivery of enzymes through biological membranes

Judit Tomsen, researcher at Nanomol Group – NANBIOSIS U6 (ICMAB-CSIC and CIBER-BBN) will defend her PhD thesis on Thursday, 15 July 2021, at 11 am in an hybrid session, from the ICMAB Seminar Room “Carles Miravitlles”. Further information and Registration to attend the PhD Thesis defense via Zoom at ICMAB-website. Supervisors: Nora Ventosa (Scientific Director of NANBIOSIS U6 Biomaterial Processing and Nanostructuring Unit and leader of Nanomol Group of CIBER-BBN- ICMAB-CSIC Elisabet González, Nanomol Group of CIBER-BBN – ICMAB-CSIC Abstract: Liposomes are lipid-based nanovesicles widely explored as nanocarriers for the transport of biomolecules or drugs of interest to the place of action, and for the development of new[...]

12 Jul

Jaume Veciana awarded by the Catalan Society of Chemistry with the Prize to the Scientific Excellence

Jaume Veciana Miró, Director of NANBIOSIS, has been awarded by the Catalan Society of Chemistry in its 2021 edition of Awards in research, education and dissemination with the Prize to the Scientific Excellence for his scientific career.[...]

06 Jul

New Nanomedicines for the topical treatment of complex wounds

Acute and chronic wounds are a growing global health problem. The incidence of non-healing chronic wounds has exponentially increased with the aging of the population and chronic diseases. It has been estimated that there is a 2% prevalence of chronic wounds in the general population, which is associated with an annual estimated cost of more than US$50 billion. Biomaterial-based treatments are helpful in improving small-sized and uncomplicated ulcers. Biologic molecules, named epidermal growth factors (EGFs) have demonstrated potent therapeutic efficacy along with limited side effects, however, exogenous EGF is rapidly cleared from the topical application site. Jaume Veciana, Nora Ventosa[...]

26 Mar

A new european infrastructure will facilitate the transfer of nano-pharmaceuticals from the lab to the clinic

Launch of the cross-european PHOENIX project, which will provide a new infrastructure available to research laboratories, SMEs and start-ups to facilitate the transfer of nano-pharmaceuticals from the laboratory to clinical practice. PHOENIX will have a duration of 4 years and a total budget of 14.45 million euros. Two CSIC Institutes, ICMAB (CSIC) and INMA (CSIC-UNIZAR), and one CSIC spin-off, Nanomol Technologies, participate in the project, will count with the expertise of NANBIOSIS unit 6 (from CIBER-BBN and ICMAB-CSIC), led by Nora Ventosa. PHOENIX is an innovation project funded by EU’s Horizon2020 Framework Programme aimed to provide services for the development, characterization, testing,[...]

26 Feb

A more effective nanomedicine has been developed for the treatment of Fabry rare disease.

28 February: International Rare Disease Day This is one of the major achievements of the European Smart4Fabry project, which is now coming to an end after four years of work.The results have been made possible by nanotechnology and the approach developed could be applied to other drugs in the future.The new drug improves on current treatments and helps reduce costs and improve patients’ quality of life. Barcelona, 26 February 2021.- The advance of nanomedicine opens up new possibilities in the development of drugs, such as the one recently developed for the rare disease Fabry, with improved efficacy compared to existing[...]

11 Feb

NANBIOSIS Scientific Women in the International Day of Women and Girls in Science

Today February 11 is the International Day of Women and Girls in Science, a day to raise awareness of the gender gap in science and technology. According to the United Nations, while yet women and girls continue to be excluded from participating fully in science, science and gender equality are vital to achieve the internationally agreed development goals, including the 2030 Agenda for Sustainable Development. Thus, in recent years, the international community has made a great effort to inspire and promote the participation of women and girls in science. NANBIOSIS wants to acknowledge the efforts made by scientific women who struggle every day to contribut[...]

27 Jan

Smart-4-Fabry final workshop

Next Wedneday, February 3, 2021 will take place the on-line event Smart-4-Fabry Final Workshop. Smart-4-Fabry is a european project, coordinated by CIBER-BBN wich has been developed during four years. This project is a sign of cooperation at European level to boost nanomedicine development and translation to clinical stages. This project is also a clear example of the relevance of access to advanced research infrastructures as NANBIOSIS -ICTS. Four NANBIOSIS units have collaborated and contributed to Smart-4-Fabry development: U1 Protein Production Platform (PPP) at IBB-UABU3 Synthesis of Peptides Unit at IQAC-CSICU6 Biomaterial Processing and Nanostructuring Unit at ICMAB-CSICU20 In Vivo[...]

U6-Biomaterial Processing and Nanostructuring Unit

• Read More

U9. Synthesis of Nanoparticles Unit

- Scientific Director: Prof. Jesús Santamaría jesus.santamaria@unizar.es

- Scientific Coordinator: Dr. Gema Martínez gemamar@unizar.es

- Entities: Institute of Nanoscience of Aragón (INA)

- Address: R&D Building, Campus Río Ebro, Universidad de Zaragoza. C/Mariano Esquirl S/n, 50018, Zaragoza, Spain

- Phone: 34 976 761000 ext. 3496

- Web: I3A-UZ

Order request

Description

This unit, integrated in the Nanostructured Films and Particles Group at the Institute of Nanoscience of Aragón (INA) coordinated by Dr. Jesús Santamaría, has as objective the synthesis of nanoparticles with applications in biomedicine. The unit provides an automated system for the synthesis of nanoparticles using laser-induced pyrolysis of chemical precursors in gas and/or aerosol phase, which enable either individual nanoparticles or biocompatible hybrid nanostructures to be produced in large quantities. In addition, this facility is able to draw on a wide range of nanoparticles fabrication technique, as well as having the necessary specialized personnel, to undertake exhaustive characterization of the microstructure, chemical composition, particles size and distribution of sizes, as well as magnetic, optical and colloidal properties and degree of biological functionality of the synthesized material.